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Background and the purpose of the study: Piperazinyl quinolones such as ciprofloxacin, ofloxacin and
levofloxacin are an important group of quinolone antimicrobials which are widely used in the treatment of various
infectious diseases. In the present study, we synthesized a new series of levofloxacin derivatives and evaluated their
antibacterial activities.
Methods: The N-substituted analogs of levofloxacin 6a–j were prepared by nucleophilic reaction of N-desmethyl
levofloxacin 11 with thienylethyl bromide derivatives 8 or 9. All target compounds were tested using conventional
agar dilution method in comparison to levofloxacin and N-desmethyl levofloxacin and their MIC values were
determined against a panel of Gram-positive and Gram-negative bacteria.
Results: All compounds showed significant antibacterial activities against Gram-positive bacteria
(MIC = 0.04-6.25 μg/mL); however, the activity against Gram-negative bacteria was lower (MIC = 1.56–100 μg/mL).
As is evident from the data, oxime derivatives 6e, 6h and 6i are superior in inhibiting the growth of Gram-positive
bacteria (MIC = 0.04–0.19 μg/mL), and their activities were found to be 5–25 times better than N-desmethyl
levofloxacin 11 and equal or better than levofloxacin 4.
Conclusion: We have designed and synthesized novel quinolone derivatives bearing functionalized thienylethyl
moiety on the piperazine ring of levofloxacin. The results of antibacterial screening against Gram-positive and
Gram-negative bacteria revealed that the introduction of functionalized thienylethyl moiety on the piperazine ring
of levofloxacin can improve the activity against Gram-positive bacteria. Gram-positive bacteria are responsible for a
wide range of infectious diseases, and rising resistance in this group is causing increasing concern. Thus, this study
introduces structural features of levofloxacin scaffold for development of new candidates in the field of anti-Gram
positive chemotherapy
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Fluoroquinolones which are synthetic antibacterial agents
are useful for the treatment of urinary tract infections, soft
tissue infections, respiratory infections, typhoid fever, sexu-
ally transmitted diseases, bone-joint infections, community-
acquired pneumonia, acute bronchitis, and sinusitis [1].* Correspondence: aforoumadi@yahoo.com
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Sciences, Tehran, Iran
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the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumFluoroquinolones consist of a bicyclic ring structure in
which there is a substitution at position N-1; most of the
current agents have a carboxyl group at position 3, a keto
group at position 4, a fluorine atom at position 6 and a
nitrogen heterocyclic moiety at the C-7 position [2].
Piperazine substitution at C-7 position has resulted in a
wide range of clinically useful fluoroquinolone antibac-
terial agents namely norfloxacin (1), ciprofloxacin (2),
ofloxacin (3) and levofloxacin (4) [3,4]. Fluoroquinolones
with 7-piperazinyl moiety have been reported to possess
potent antibacterial activity [5,6]. Levofloxacin, a chiralMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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quinolone antibacterial that departs from the typical qui-
nolones substructure by having a fused ring connecting
the N1 to C8 position [7]. This ring is connected with an
ether moiety at C8 [8]. Levofloxacin has been reported to
be active in vitro against both Gram-positive and Gram-
negative bacteria. Two major targets have been identified
for levofloxacin activity, topoisomerase II (DNA-gyrase) in
Gram-negative bacteria and topoisomerase IV in Gram-
positive bacteria [9]. According to the inhibition mechan-
isms of the quinolones, the site near the C-7 substituent is
regarded as drug-enzyme interaction domain and controls
the spectrum and selectivity of quinolone molecule [10].
Over the past few years, we were particularly interested
in the synthesis and evaluation of N-substituted 7-
piperazinyl quinolones [5] for their antibacterial activities
[11-16]. Although the nature of the C-7 substituent was
known to influence quinolone activity in bacteria, we iden-
tified that addition of a certain bulky group as a particular
chemical modification is permitted at the C-7 position of
the piperazine ring and allows manipulation of selectivity
and potency. Previously, we described the synthesis and
antibacterial activity of certain piperazinyl quinolones
(Figure 1), with 2-(thiophen-3-yl)-2-oxoethyl or 2-(thiophen-
3-yl)-2-oxyiminoethyl moieties attached to the piperazine
ring at the C-7 position [12]. In the present study, we have
aimed to achieve new quinolone antibacterial, by preparing
the levofloxacin derivatives 6a–j carrying a 2-thienyl-2-
oxoethyl or a 2-thienyl-2-oxyiminoethyl moiety attached to
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Figure 1 The structures of some known fluoroquinolones (1-5) and thMaterial and methods
Chemistry
Chemicals and all solvents used in this study were
purchased from Merck AG and Aldrich Chemical.
Melting points were determined on a Kofler hot stage
apparatus and are uncorrected. The IR spectra were
obtained on a Shimadzu 470 spectrophotometer (potas-
sium bromide disks). 1H-NMR spectra were measured
using a Bruker 400 spectrometer, and chemical shifts
are expressed as δ (ppm) with tetramethylsilane as in-
ternal standard. Merck silica gel 60 F254 plates were
used for analytical TLC. Yields are of purified product
and were not optimized. The intermediate compounds
9 were prepared according to the literature [12,14]. N-
Desmethyl levofloxacin was prepared as previously
described method [17]. The synthetic route for ac-
hieving the target compounds 6a–j was depicted in
Figure 2.
General procedure for the synthesis of compounds 6a–j
A mixture of thienylethyl bromide derivatives 8 or 9
(0.55 mmol), N-desmethyl levofloxacin 11 (174 mg,
0.5 mmol) and NaHCO3 (42 mg, 0.5 mmol) in DMF
(5 mL) was stirred at room temperature for 6–10 h.
After consumption of N-desmethyl levofloxacin 11
(monitored by TLC), water (20 mL) was added and the
precipitate was filtered, washed with water and crystal-
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Figure 2 Synthesis of levofloxacin derivatives 6a–j. Reagents and conditions :(a) CuBr2, CHCl3–EtOAc, reflux;(b) HONH2·HCl orMeONH2·HCl or
BnONH2·HCl, MeOH, r.t.; (c) piperazine; (d) DMF, NaHCO3, r.t.




Yield: 31%; mp 165–166°C; IR (KBr) cm−1: 1622, 1721 (C =
O). 1H-NMR (DMSO-d6): 1.45 (d, 3H, CH3, J = 6.0 Hz),
3.26–3.33 (m, 4H, piperazine), 3.38–3.42 (m, 4H, pipera-
zine), 3.49 (s, 2H, CH2), 3.75 (s, 1H, CH2), 4.39 (d, 1H,
CH2, J = 10.9 Hz), 4.60 (d, 1H, CH2, J = 10.9 Hz), 4.87 (m,
1H, CH-Me), 7.53 (d, 1H, thiophene, J = 5.0 Hz), 7.58–7.65
(m, 1H, thiophene), 7.81 (d, 1H, H8, J = 11.9 Hz), 8.99




Yield: 26%; mp 156–157°C; IR (KBr) cm−1: 1620, 1719
(C = O). 1H-NMR (DMSO-d6): 1.43 (d, 3H, CH3, J =
6.2 Hz), 3.27–3.34 (m, 4H, piperazine), 3.36–3.41 (m,
4H, piperazine), 3.47 (s, 2H, CH2), 3.77 (s, 1H, CH2),
4.40 (d, 1H, CH2, J = 11.0 Hz), 4.59 (d, 1H, CH2, J =
11.0 Hz), 4.85 (m, 1H, CH-Me), 7.52 (d, 1H, thiophene,
J = 5.0 Hz), 7.56–7.64 (m, 1H, thiophene), 7.79 (d, 1H,




Yield: 24%; mp 180–181°C; IR (KBr) cm−1: 1626, 1717 (C
=O). 1H-NMR (DMSO-d6): 1.62 (d, 3H, CH3, J = 5.3 Hz),2.47–2.70 (m, 4H, piperazine), 3.34–3.42 (m, 4H, pipera-
zine), 3.51 and 3.96 (two s, 2H, CH2, E- and Z-isomers),
4.04 and 4.07 (two s, 3H, OMe, E- and Z-isomers), 4.31–
4.37 (m, 1H, CH2), 4.42–4.52 (m, 1H, CH2), 4.47–4.51 (m,
1H, CH-Me), 7.04 and 7.08 (two d, 1H, thiophene, E- and
Z-isomers, J = 4.0 Hz), 7.63 and 7.69 (two d, 1H, thio-
phene, E- and Z-isomers, J = 4.0 Hz), 7.73 (d, 1H, H8, J =
12.3 Hz), 8.61 (s, 1H, H5), 15.01 (s, 1H, COOH).
10-(4-(2-(benzyloxyimino)-2-(5-chlorothiophen-2-yl) ethyl)
piperazin-1-yl)-9-fluoro-3-methyl-7-oxo-3, 7-dihydro-2H-[1,
4]oxazino [2, 3, 4-ij]quinoline-6-carboxylic acid (6d)
Yield: 15%; mp 143–144°C; IR (KBr) cm−1: 1H-NMR
(DMSO-d6): 1.62 (d, 3H, CH3, J = 6.6 Hz), 2.47–2.72 (m,
4H, piperazine), 3.28–3.43 (m, 4H, piperazine), 3.50 and
3.65 (two s, 2H, CH2, E- and Z-isomers), 4.34 (d, 1H,
CH2, J = 6.6 Hz), 4.47 (d, 1H, CH2, J = 6.6 Hz), 5.19 and
5.26 (two s, 2H, OCH2, E- and Z-isomers), 5.32 (s, 1H,
CH-Me), 6.82 and 6.84 (two d, 1H, thiophene, E- and Z-
isomers, J = 4.0 Hz), 6.91 and 6.94 (two d, 1H, thiophene,
E- and Z-isomers, J = 4.0 Hz), 7.36–7.40 (m, 5H, phenyl),





Yield: 16%; mp 314–315°C; IR (KBr) cm−1: 1623 (C =O).
1H-NMR (DMSO-d6): 1.40–1.58 (m, 3H, CH3), 2.45-78
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2H, CH2), 4.35 (d, 1H, CH2, J = 10.4 Hz), 4.57 (d, 1H, CH2,
J = 10.4 Hz), 4.58–4.49 (m, 1H, CH-Me), 7.20–7.40 (m,
1H, thiophene), 7.56 (d, 1H, H8, J = 11.6 Hz), 7.66–7.76
(m, 1H, thiophene), 7.82–7.90 (m, 1H, thiophene), 8.96




Yield: 19%; mp 224–225°C; IR (KBr) cm−1: 1719 (C =O).
1H-NMR (DMSO-d6): 1.43 (d, 3H, CH3, J = 4.3 Hz),
2.53–2.63 (m, 4H, piperazine), 3.23–3.31(m, 4H, pipera-
zine), 3.50 and 3.66 (two s, 2H, CH2, E- and Z-isomers),
3.89 (s, 3H, OCH3), 4.36 (d, 1H, CH2, J = 8.8 Hz), 4.57
(d, 1H, CH2, J = 8.8 Hz), 4.90–4.94 (m, 1H, CH-Me),
7.08–7.23 (m, 1H, thiophene), 7.54 and 7.76 (two d, 1H,
thiophene, E- and Z-isomers, J = 4.2 Hz), 7.79 and 7.83
(two d, 1H, thiophene, E- and Z-isomers, J = 4.2 Hz),





Yield: 17%; mp 157–158°C; IR (KBr) cm−1: 1720 (C =O).
1H-NMR (DMSO-d6): 1.44(d, 3H, CH3, J = 7.5 Hz),
2.53–2.61 (m, 4H, piperazine), 3.23–3.38 (m, 4H, pipera-
zine), 3.50 and 3.69 (two s, 2H, CH2, E- and Z-isomers),
4.65–4.80 (m, 1H, CH2), 4.90–4.97 (m, 1H, CH-Me),
5.17 and 5.28 (two s, 2H, OCH2, E- and Z-isomers),
7.06–7.22(m, 1H, thiophene), 7.30–7.42 (m, 5H, phenyl),
7.52 and 7.59 (d, 1H, thiophene, J = 4.4 Hz, Z-isomer),
7.77 and 7.89 (two d, 1H, thiophene, E- and Z-isomers,
J = 4.4 Hz), 7.94 (d, 1H, H8, J = 10.0 Hz), 8.96 (s, 1H, H5),




Yield: 22%; mp 354–356°C; IR (KBr) cm−1: 1631, 1719
(C = O). 1H-NMR (DMSO-d6): 1.40–1.48 (m, 3H, CH3),
2.53–2.60 (m, 4H, piperazine), 3.37–3.43 (m, 4H, pipera-
zine), 4.31–4.38 (m, 1H, CH2), 4.52–4.60 (m, 1H, CH2),
4.84–4.92 (m, 1H, CH-Me), 7.50–7.60 (m, 2H, thio-
phene), 7.72 (d, 1H, thiophene, J = 4.5 Hz), 8.38–8.43 (m,





Yield: 18%; mp 156–157°C; IR (KBr) cm−1: 1630, 1721
(C = O). 1H-NMR (DMSO-d6): 1.42 (d, 3H, CH3, J =4.8 Hz), 2.51–2.65 (m, 4H, piperazine), 3.24–3.32 (m,
4H, piperazine), 3.52 (s, 2H, CH2), 3.91 (s, 3H, OCH3),
4.37 (d, 1H, CH2, J = 8.7 Hz), 4.59 (d, 1H, CH2, J =
8.7 Hz), 4.91–4.95 (m, 1H, CH-Me), 7.07–7.13 (m, 1H,
thiophene), 7.54 (d, 1H, thiophene, J = 4.0 Hz), 7.85 (d,
1H, thiophene, J = 4.0 Hz), 7.90 (d, 1H, H8, J = 10.3 Hz),




Yield: 17%; mp 162–163°C; IR (KBr) cm−1: 1621, 1716 (C
=O). 1H-NMR (DMSO-d6): 1.43 (d, 3H, CH3, J = 6.8 Hz),
2.40–2.67 (m, 4H, piperazine), 3.17–3.44 (m, 4H, pipera-
zine), 3.54 and 3.65 (two s, 2H, CH2, E- and Z-isomers),
4.54–4.58 (m, 1H, CH2), 4.90–4.93 (m, 1H, CH-Me), 5.14
and 5.28 (two s, 2H, OCH2, E- and Z-isomers), 7.06–7.20
(m, 1H, thiophene), 7.39 (d, 1H, thiophene, J = 4.0 Hz, Z-
isomer), 7.44 (d, 1H, thiophene, J = 4.0 Hz, Z-isomer),
7.48–7.68 (m, 5H, phenyl), 7.68 (d, 1H, thiophene, J =
4.0 Hz, E-isomer), 8.31 (d, 1H, thiophene, J = 4.0 Hz, Z-
isomer), 8.38 (d, 1H, thiophene, J = 4.4 Hz, E-isomer), 8.01
(s, 1H, H8), 8.96 (s, 1H, H5), 15.01 (s, 1H, COOH).
Antimicrobial activity
Compounds 6a–j were screened for their antibacterial ac-
tivity against Gram-positive (Staphylococcus aureus ATCC
6538, Staphylococcus epidermidis ATCC 12228, Bacillus
subtilis ATCC 6633) and Gram-negative (E. coli ATCC
8739, Pseudomonas aeruginosa ATCC 9027, Klebsiella
pneumoniae ATCC 10031) bacteria by the conventional
agar dilution method [18]. Two-fold serial dilutions of the
compounds and reference drugs (levofloxacin and N-des-
methyl levofloxacin) were prepared in Mueller-Hinton agar.
Drugs (10.0 mg) were dissolved in DMSO (1 mL) and the
solution was diluted with water (9 mL). Further progressive
double dilution with melted Mueller-Hinton agar was per-
formed to obtain the required concentrations of 100, 50,
25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.19, 0.09, 0.04, 0.02 and
0.01 μg/mL. Petri-dishes were inoculated with 1–5 × 104
colony-forming units (cfu) and incubated at 37°C for 18 h.
The minimum inhibitory concentration (MIC) was defined
as the lowest concentration of the test compound, which
resulted in no visible growth on the plate. To insure that
the solvent had no effect on bacterial growth, a control test
was performed with test medium supplemented with
DMSO at the same dilutions as used in the experiment.
Results and discussion
As summarized in Figure 2, the N-substituted analogs of
levofloxacin 6a–j were prepared by nucleophilic reaction of
N-desmethyl levofloxacin 11 with thienylethyl bromide
derivatives 8 or 9 employing reaction sequences previously
described by us for the preparation of other N-substituted









Compound R Y S. aureus S. epidermidis B. subtilis E. coli P. aeruginosa K. pneumoniae
6a
SBr




O 0.39 0.19 0.09 1.56 6.25 1.56
6c
SCl
NOCH3 0.78 0.39 0.19 50 50 12.5
6d
SCl
NOBn 3.125 1.56 0.78 50 100 100
6e
S
NOH 0.19 0.19 0.19 3.125 25 3.125
6f
S
NOCH3 0.39 0.19 0.09 50 100 25
6g
S
NOBn 6.25 3.125 0.78 100 100 50
6h
S
NOH 0.19 0.09 0.04 3.125 12.5 3.125
6i
S
NOCH3 0.19 0.19 0.09 100 100 50
6j
S
NOBn 6.25 3.125 0.39 50 100 25
Levofloxacin 0.25 0.25 0.5 0.03 4 0.25
N-Desmethyl levofloxacin 4 1 1 0.012 >4 0.25
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synthesized by the reaction of ketone 8 with hydroxylamine
hydrochloride or O-methylhydroxylamine hydrochloride orO-benzylhydroxylamine hydrochloride [12,14]. On the
other hand, the piperazinyl quinolone (11, N-desmethyl
levofloxacin) was prepared according to the known method
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dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxa-
zine-6-carboxylic acid 10. Reaction of N-desmethyl levo-
floxacin 11 with thienyl ethyl bromide derivatives 8 or 9 in
DMF, in the presence of NaHCO3 at room temperature
afforded corresponding ketones 6a,b and oxime derivatives
6c–j, respectively.
The minimum inhibitory concentrations (MICs, μg/mL)
obtained for compounds 6a–j are presented in Table 1. In
general, Table 1 reveals that higher susceptibilities were
observed with Gram-positive and poorer susceptibilities
with Gram-negative bacteria. The MIC values of ketones
6a,b and oximes 6c–j against Gram-positive strains indi-
cate that most compounds possessed a comparable or bet-
ter activity (MIC = 0.04–3.12 μg/mL) with respect to N-
desmethyl levofloxacin 11 and levofloxacin 4 (MIC = 0.25–
4 μg/mL). As is evident from the data, oximes 6e, 6h and 6i
followed by ketone 6a are superior in inhibiting the growth
of Gram-positives (MIC= 0.04–0.19 μg/mL), and their ac-
tivities were found to be 5–25 times better than N-des-
methyl levofloxacin 11 and equal or better than
levofloxacin 4. In general, most compounds showed weak
to good activity (MIC = 1.56–100 μg/mL) against Gram-
negative bacteria. Compound 6b was the most potent
against E. coli, Pseudomonas aeruginosa and Klebsiella
pneumonia (MIC = 1.56–6.25 μg/mL). Comparison be-
tween MIC values of 2-thienyl drivatives 6e–g and 3-
thienyl compounds 6h–j revealed that the corresponding
regioisomers have a same antibacterial activity and this
modification cannot improve the activity. Also, etherifica-
tion of oximes by methyl or benzyl groups dramatically
diminished the activity against Gram-negatives. However,
by O-methylation, the activity against Gram-positive bac-
teria was maintained. In addition, by comparison of 5-
chlorothiophene derivatives 6c,d and corresponding unsub-
stituted analogs 6f,g it could be concluded that halogen
substituent is not important for activity.Competing interests
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